National Drug Schedules

NOTE - Effective December 19, 2013, Schedule F to the Food and Drug Regulationswas repealed and replaced by a list of prescription drugs, called the Prescription Drug List. Therefore, all entries in the National Drug Schedules (NDS) whose footnote indicates that they appear in Schedule F (F1/F2) should now be considered part of the Prescription Drug List (PDL).

Entries whose footnote indicates that they are "Schedule F Recommended" (FR) should now be considered recommended for addition to the PDL. Some of the "Schedule F Recommended" entries may have been added or will shortly be added to the PDL by Health Canada, but either way these entries will continue to be listed in Schedule I of the NDS.

For more information on the Prescription Drug List, please consult the Health Canada website.

Drug Product Database
Licensed Natural Health Products Database

Print Friendly Export to CSV

Drug Name	Comment	Schedule	Date
Rabeprazole and its salts^F1		I	JUL / 03
Rabies immune globulin		I	FEB / 02
Rabies vaccine		I	FEB / 02
Racemethionine		II	SEP / 98
Racemethorphan^N		I	JUN / 02
Racemoramide^N		I	JUN / 02
Racemorphan^N		I	JUN / 02
Raloxifene and its salts^F1		I	SEP / 99
Raltegravir and its salts^F1		I	MAY / 09
Raltitrexed and its salts and derivatives^F1		I	SEP / 98
Ramipril and its salts and derivatives^F1		I	SEP / 98
Ramucirumab^PDL		I	OCT / 15
Ranibizumab^F1		I	SEP / 08
Ranitidine or its salts^PDL	except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn	I	DEC / 13
Ranitidine or its salts.	when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4,500 mg of ranitidine	III	MAR / 08
Ranitidine or its salts..	when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 4,500 mg of ranitidine	U	FEB / 07
Rasagiline and its salts^F1		I	APR / 08
Rasburicase^F1		I	APR / 07
Raubasine and its salts^F1		I	SEP / 98
Rauwolfia^F1		I	SEP / 98
Remifentanil^N		I	JUN / 02
Remoxipride and its salts^F1		I	SEP / 98
Repaglinide and its salts and derivatives^F1		I	MAY / 00
Rescinnamine and its salts^F1		I	SEP / 98
Reserpine and its salts^F2		I	SEP / 98
Reslizumab^PDL		I	JUN / 17
Resocortol and its derivatives.^FR			AUG / 06
Resocortol and its derivatives..^F1		I	OCT / 07
Retapamulin^F1		I	OCT / 09
Reviparin and its salts^F1		I	SEP / 98
Rho D immune globulin		I	FEB / 02
Ribavirin^F1		I	SEP / 98
Ribociclib or its salts^PDL		I	MAY / 18
Rifabutin and its salts^F1		I	SEP / 98
Rifampin and its salts and derivatives^F1		I	SEP / 98
Rilpivirine or its salts or derivatives^PDL	including but not limited to rilpivirine hydrochloride	I	DEC / 13
Riluzole and its salts^F1		I	DEC / 02
Risedronic acid and its salts^F1		I	MAR / 01
Risperidone and its salts^F1		I	SEP / 98
Ritodrine and its salts^F1		I	SEP / 98
Ritonavir^F1		I	SEP / 98
Rituximab^F1		I	DEC / 01
Rivaroxaban^F1		I	MAY / 10
Rivastigmine and its salts^F1		I	SEP / 99
Rocuronium bromide^F1		I	SEP / 98
Rofecoxib^F1		I	MAR / 01
Roflumilast or its salts or derivatives^PDL		I	DEC / 13
Romifidine and its salts^F1		I	MAY / 04
Romiplostim^F1		I	MAR / 11
Ronidazole and its salts and derivatives^F2		I	SEP / 98
Ropinirole and its salts^F1		I	SEP / 98
Rose Bengal		II	SEP / 98
Rosiglitazone and its salts^F1		I	DEC / 01
Rosoxacin and its salts^F1		I	SEP / 98
Rosuvastatin and its salts^F1		I	JUN / 06
Rubella vaccine		II	DEC / 98
Rue and its preparations and extracts		II	SEP / 98
Rufinamide or its derivatives^PDL		I	DEC / 13
Rupatadine^PDL		I	FEB / 17

59 result(s)

Print Friendly Export to CSV

Footnotes

C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
C4: drug is in the Controlled Drugs and Substances Act
C5: drug is in the Regulations Under CDSA
CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
NR: drug has not been reviewed by NDSAC
PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
U: drug has been reviewed by NDSAC and is unscheduled

National Drug Schedules

Search: National Drug Schedules

59 result(s)

Footnotes